Sevirumab

Drug Profile

Sevirumab

Alternative Names: EV2 7; MSL 109; Protovir; SDZ MSL 109

Latest Information Update: 22 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Developer Novartis; PDL BioPharma
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cytomegalovirus infections

Most Recent Events

  • 22 Jul 2016 Changed the NDR date to 2007 because NCT00002016 was completed in 2005
  • 23 Jun 2007 No-Development-Reported for Cytomegalovirus infections in USA (IV) (NCT00002016)
  • 17 May 2001 No-Development-Reported for Cytomegalovirus infections in Switzerland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top